Moderna (MRNA) EBIAT (2017 - 2025)
Historic EBIAT for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to -$200.0 million.
- Moderna's EBIAT fell 163846.15% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 4010.79%. This contributed to the annual value of -$3.6 billion for FY2024, which is 2445.91% up from last year.
- Latest data reveals that Moderna reported EBIAT of -$200.0 million as of Q3 2025, which was down 163846.15% from -$825.0 million recorded in Q2 2025.
- Moderna's 5-year EBIAT high stood at $4.9 billion for Q4 2021, and its period low was -$3.6 billion during Q3 2023.
- Over the past 5 years, Moderna's median EBIAT value was $79.0 million (recorded in 2023), while the average stood at $541.7 million.
- As far as peak fluctuations go, Moderna's EBIAT skyrocketed by 247606.84% in 2021, and later plummeted by 163846.15% in 2025.
- Moderna's EBIAT (Quarter) stood at $4.9 billion in 2021, then tumbled by 69.91% to $1.5 billion in 2022, then plummeted by 85.19% to $217.0 million in 2023, then plummeted by 616.13% to -$1.1 billion in 2024, then soared by 82.14% to -$200.0 million in 2025.
- Its EBIAT stands at -$200.0 million for Q3 2025, versus -$825.0 million for Q2 2025 and -$971.0 million for Q1 2025.